Trial reportEuropean archives of psychiatry and clinical neuroscience2026
Diagnostic accuracy of a self-administered digital cognitive test battery for differentiating early Alzheimer's disease from controls.
Trial report in European archives of psychiatry and clinical neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06711952 (German Validation Study of the Subjective Cognitive Decline Questionnaire), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
German Validation Study of the Subjective Cognitive Decline Questionnaire (SCD-Q) and Its Potential Use in Large Cohorts
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPaper-pencil assessments face limitations in accessibility, lengthy administration, and interrater reliability. Digital tools may overcome these by offering user-friendly, non-verbal, and scalable assessments. This study investigated the diagnostic accuracy of BraincheX, a novel digital test battery focused on accessibility and usability, by comparing its subtest performance to CERAD-Plus equivalents.
methodsFifty-six participants with early AD and amyloid negative cognitively healthy controls were recruited from the LMU hospital memory clinic. Diagnostic groups were defined by amyloid positivity and clinical expert consensus according to the IWG-2 criteria. Participants completed the BraincheX digital battery and CERAD-Plus. BraincheX total score was calculated by summing standardized subtest scores. Data were analyzed using ROC analysis and the Youden Index. Correlations between subtests were examined, and group differences analyzed via ANOVA.
resultsROC analysis revealed strong diagnostic accuracy for the BraincheX total score in differentiating between early AD and controls (AUC = 0.86; optimal cut-off = - 1.51), with high sensitivity of 89.7% and moderate specificity of 68.0%. BraincheX total scores correlated with CERAD total scores (r = .73, p < .001). BraincheX demonstrated good internal consistency (Cronbach's α = 0.84). ANOVA confirmed significant group differences across all BraincheX subtests (p < .01). Individual subtests showed strong correlations with CERAD-Plus equivalents.
conclusionsFindings suggest BraincheX as a promising, accessible digital screening tool for cognitive decline, offering automated scoring, immediate feedback, and reduced examiner bias. Future research is required to validate BraincheX in larger and more diverse populations and to establish BraincheX's clinical applicability. TRIAL REGISTRY: This analysis was conducted within the framework of the prospectively registered German SCD-Q validation study (NCT06711952). The registered study protocol included digital cognitive testing as part of the assessment protocol. The present manuscript reports a secondary analysis focusing on the diagnostic performance of BraincheX.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.